Medpace price target lowered to $450 from $500 at Barclays

Barclays analyst Luke Sergott lowered the firm’s price target on Medpace (MEDP) to $450 from $500 and keeps an Equal Weight rating on the shares post the Q1 report. The company reported a “tough print” with a bookings miss, but delivered a beat on EBITDA margins and improved win rates, the analyst tells investors in a research note.